Expert predicts warfarin to become obsolete

The US study in 250 patients receiving long-term stable doses of warfarin showed that INR monitoring every 12 weeks was as safe as monitoring INR every four weeks.

Patients who had monitoring with the longer interval were in the therapeutic range 74% of the time, compared with 72% for those monitored at shorter intervals.

The president of the Stroke Society of Australasia, geriatrician Professor Richard Lindley, said the study provided reasonable evidence that three-monthly INR monitoring was feasible, but noted the trial was not ‘real life’ because any extreme INR values in the 12-week monitoring group had to be reported for safety reasons.

“[But] in an era when we probably should be moving to the newer agents, to get this evidence so late in the life of the drug, it’s a bit of a sad reflection that this sort of trial hadn’t been done decades ago,” Professor Lindley said.

“My view is that warfarin